ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck Serono Launches Geneva Spin-Off

by Rick Mullin
August 6, 2012 | APPEARED IN VOLUME 90, ISSUE 32

Merck Serono has launched the first spin-off venture resulting from a $40 million program to employ researchers whose jobs are being cut with the closure of the company’s headquarters site in Geneva. Prexton Therapeutics, formed in a partnership with Eclosion, a biotech incubator in Geneva, will pursue neurodegenerative disease therapies based on Merck Serono’s R&D portfolio for Parkinson’s disease. Merck Serono will invest $2.6 million in the venture. The end of research operations in Geneva is eliminating about 500 jobs.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment